Mammalian target of rapamycin as a target in hematological malignancies

被引：15
作者：
Kelly, Kevin R. [1 ]
Rowe, Julie H. [1 ]
Padmanabhan, Swaminathan [1 ]
Nawrocki, Steffan T. [1 ]
Carew, Jennifer S. [1 ]
机构：
[1] Univ Texas Hlth Sci Ctr San Antonio, Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
来源：
TARGETED ONCOLOGY | 2011年 / 6卷 / 01期
关键词：
mTOR; Hematological malignancies; Novel agents; Targeted therapy; ACUTE MYELOID-LEUKEMIA; MANTLE CELL LYMPHOMA; SINGLE-AGENT TEMSIROLIMUS; PHASE-II TRIAL; EVERY; WEEKS; MULTIPLE-MYELOMA; IN-VIVO; INHIBITOR EVEROLIMUS; PHOSPHOINOSITIDE; 3-KINASE; DEFOROLIMUS AP23573;
D O I：
10.1007/s11523-011-0175-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The mammalian target of rapamycin (mTOR) regulates protein synthesis in addition to cell growth and cell proliferation. Elucidation of the roles of the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway in the regulation of the pathogenesis of hematological neoplasms has led to the development and clinical evaluation of agents targeting this pathway for the treatment of leukemia and lymphomas. Clinical trials conducted to date have shown modest responses to mTOR inhibition in patients with various hematological malignancies. Novel agents that simultaneously target mTOR complex 2 (mTORC2) or AKT in addition to mTOR complex 1 (mTORC1) may offer an opportunity to improve therapeutic efficacy.
引用
收藏
页码：53 / 61
页数：9
相关论文
共 50 条
  • [41] Activation of mammalian target of rapamycin signaling in spatial learning
    Qi, Sihua
    Mizuno, Makoto
    Yonezawa, Kazuyoshi
    Nawa, Hiroyuki
    Takei, Nobuyuki
    NEUROSCIENCE RESEARCH, 2010, 68 (02) : 88 - 93
  • [42] The rationale of targeting mammalian target of rapamycin for ischemic stroke
    Chong, Zhao Zhong
    Yao, Qingqiang
    Li, Hui-Hua
    CELLULAR SIGNALLING, 2013, 25 (07) : 1598 - 1607
  • [43] Activation of the Akt/mammalian target of rapamycin pathway in myxofibrosarcomas
    Takahashi, Yusuke
    Kohashi, Kenichi
    Yamada, Yuichi
    Endo, Makoto
    Setsu, Nokitaka
    Ishii, Takeaki
    Yamamoto, Hidetaka
    Iwamoto, Yukihide
    Oda, Yoshinao
    HUMAN PATHOLOGY, 2014, 45 (05) : 984 - 993
  • [44] Mammalian Target of Rapamycin: Is It Relevant to COPD Pathogenesis or Treatment?
    Pasini, Evasio
    Flati, Vincenzo
    Comini, Laura
    Olivares, Adriana
    Bertella, Enrica
    Corsetti, Giovanni
    Vitacca, Michele
    COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2019, 16 (01) : 89 - 92
  • [45] Mammalian Target of Rapamycin: A Novel Pathway in Vascular Calcification
    Montezano, Augusto C.
    Touyz, Rhian M.
    CANADIAN JOURNAL OF CARDIOLOGY, 2014, 30 (05) : 482 - 484
  • [46] Autism spectrum disorder and mammalian target of rapamycin system
    Posar, Annio
    Visconti, Paola
    JOURNAL OF PEDIATRIC NEUROSCIENCES, 2020, 15 (02) : 164 - 165
  • [47] Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
    Henry Querfurth
    Han-Kyu Lee
    Molecular Neurodegeneration, 16
  • [48] Indications and Effectiveness of the Mammalian Target of Rapamycin in Liver Transplantation
    Sanchez Antolin, G.
    Garcia Pajares, F.
    Lorenzo Pelayo, S.
    Herranz Bachiller, M. T.
    Almohalla, C.
    Velicia, R.
    Caro Paton, A.
    TRANSPLANTATION PROCEEDINGS, 2011, 43 (03) : 714 - 717
  • [49] Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents
    Mohindra, Nisha A.
    Platanias, Leonidas C.
    LEUKEMIA & LYMPHOMA, 2015, 56 (09) : 2518 - 2523
  • [50] Driving neural regeneration through the mammalian target of rapamycin
    Kenneth Maiese
    Neural Regeneration Research, 2014, 9 (15) : 1413 - 1417
12345